Daiichi Sankyo's Enhertu Wins EU Approval as First Tumor-Agnostic HER2 Therapy
Event summary
- Enhertu® (trastuzumab deruxtecan) approved in the EU for previously treated HER2 positive metastatic solid tumors, marking its first tumor-agnostic approval.
- $25 million milestone payment due from AstraZeneca to Daiichi Sankyo following the approval.
- Approval based on results from DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02 phase 2 trials showing significant response rates across multiple tumor types.
- Enhertu is now approved for six indications in the EU, expanding its market potential.
The big picture
This approval solidifies Enhertu's position as a leading HER2-directed therapy, expanding its use beyond traditional indications. The tumor-agnostic approach aligns with the broader trend toward precision medicine, where treatments are tailored to molecular characteristics rather than tumor origin. Daiichi Sankyo and AstraZeneca's collaboration continues to drive innovation in oncology, potentially reshaping treatment paradigms for multiple cancer types.
What we're watching
- Market Expansion
- The pace at which Enhertu gains traction in new tumor types beyond breast, gastric, and lung cancers.
- Regulatory Progress
- Additional regulatory submissions underway in the EU for combination therapies with pertuzumab.
- Commercial Dynamics
- How Daiichi Sankyo and AstraZeneca will leverage this approval to drive sales and market share in oncology.
Related topics